Render Target: STATIC
Render Timestamp:
6/9/2026, 6:28:32 AM EDT
6/9/2026, 10:28:32 AM UTC
Commit: 33ae406c5df2bbc7a7d3c17605228fbeff8ea416
XML generation date: 2025-03-07 13:10:18.346
Product last modified at: 2025-12-21T22:57:32.902Z
Cell Signaling Technology Logo - Extra Large
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159
  1. Products /
  2. Cytokines & Growth Factors /
  3. Human Insulin-like Growth Factor II (hIGF-II)

Human Insulin-like Growth Factor II (hIGF-II) #5238

Inquiry Info. # 5238

Please see our recommended alternatives.

    Product Information

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hIGF-II.

    Storage

    Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 6
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIGF-II. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg hIGF-II.
    Activity The bioactivity of recombinant hIGF-II was determined in a cell proliferation assay using primary human dermal fibroblasts. The ED50 of each lot is between 10-20 ng/ml.
    Molecular Formula Recombinant hIGF-II does not have a Met on the amino terminus and has a calculated MW of 7,606. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal AYRPS of recombinant hIGF-II was verified by amino acid sequencing.

    Source / Purification

    Recombinant human IGF-II (hIGF-II) Ala25-Glu94 (Accession # P01344-2) was produced in E. coli at Cell Signaling Technology.

    Background

    IGF-II is a potent cellular mitogen that is closely related to IGF-I (1). IGF-II is primarily produced by the liver and is frequently overexpressed in tumors (1,2). IGF-II binds to the IGF-IR, activating the AKT, mTOR, ERK, and JNK pathways (1). IGF-II signaling is regulated by several distinct mechanisms. First, IGF binding proteins (IGFBPs) bind to IGF-II and block interactions with the IGF-IR (1-3). Second, the IGF-IIR, binds to and acts as a molecular trap for IGF-II (1-3). Lastly, the IGF2 gene is an imprinted gene, and loss of imprinting leads to increased IGF-II levels (1-3). Aberrant levels of IGF-II are associated with Wilms tumor, Beckwith-Wiedmann syndrome, and colorectal cancer (1,2).

    Alternate Names

    IGF; IGF-2

    Database Links

    UniProt ID: P01344


    Entrez-Gene Id: 3481


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.